

PIIL



Proteomics International

LABORATORIES LTD

Corporate Presentation

| Melbourne & Sydney

Proactive Investors

| 11th & 12th April 2017

**Global leader in
predictive diagnostics**

ASX: PIQ



Disclaimer & forward-looking statements



This Presentation is provided by Proteomics International Laboratories Ltd (PILL, the Company).

You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or their associates in deciding whether or not to seek to purchase the shares of the Company. This is not an offer to subscribe for securities in the Company.

The Presentation may contain quantitative statements of anticipated future performance such as projections, forecasts, calculations, forward-looking statements or estimates all of which are based on certain assumptions (Forward Looking Statements). The Forward Looking Statements may involve subjective judgements and are based on a large number of assumptions and are subject to significant uncertainties and contingencies, many of which are outside the control of the Company and may not prove to be correct.

No representation or warranty is made that any Forward Looking Statements will be achieved, or occur, or that the assumptions upon which they are based are reasonable or the calculations from which they have been derived are correct. Actual future events may vary significantly from the Forward Looking Statements. Each Recipient should undertake its own independent review of the Forward Looking Statements, including the assumptions on which they are based and the financial calculations from which they are derived.

PIQ corporate overview




Capital Structure

ASX code	PIQ
Shares on issue	59m
Market capitalisation (@ 22c)	\$13.0m
Listed (@ 20c); raised \$3m	Apr 2015
Placement/SPP (@ 24c); \$2m	Dec 2016
6 month price range	30c-17c

Shareholders

Top 20 Shareholders	64.6%
Major Shareholders	
Lipscombe	27.5%
XYLO PL	10.6%
Dunlop/Randolph Res PL	9.2%
HSBC Nominees	3.1%
Sparrow Holdings PL	1.8%



Balance sheet and P&L

Income 2015-16	\$1.4m
Cash burn 2015-16	\$1.3m
Income 2016-17 (est.)	\$1.9m
Cash burn 2016-17 (est.)	\$1.0m
Cash at Dec 31 st 2016	\$2.4m


Introducing PIQ



- **Revenue generating** company – Est'd 2001
- **Global leader & innovator** in field of proteomics
- **World's first company** to receive ISO 17025 laboratory accreditation for proteomics services
- **Diversified** business model
- World first diagnostic test at **commercialisation stage**
- Proven technology with **patents granted**
- Operates from purpose built, **state-of-the art facilities** at the Harry Perkins Institute of Medical Research in Perth, Western Australia
- **Asian focus** with global reach



Quality is Assured



A world leading predictive diagnostic test - PromarkerD



Without PromarkerD



With PromarkerD



PromarkerD in brief



Predictive diagnostic test for diabetic kidney disease

The Problem

- International Diabetes Foundation estimates **415 million people** globally have diabetes
- According to US Centre for Disease Control, **35% of adults with diabetes have chronic kidney disease**; there is **no early detection test** currently available

The Solution

- Clinical study: 576 diabetic patients followed for 4 years
- A standard blood test used to produce a protein “fingerprint”

PromarkerD **predicted** 95% of the patients who were previously kidney-disease free and go on to develop chronic kidney disease



PromarkerD - routes to market



IVD



CDx



LDT

Income streams

- licensing fees
- upfront payments
- royalties



IVD = In Vitro Diagnostic

CDx = Companion Diagnostic

LDT = Laboratory Developed Test

PromarkerD

Market size

Country	Population	Diabetes cases	Deal NPV
Dominican Republic	11m	505,700	US\$1.5m
Singapore	6m	541,600	
Japan	126m	7,202,200	
USA	324m	29,251,600	
China	1,382m	109,649,100	

PromarkerD: milestones



Stages

Timing

- Platform technology established
- Predictive diagnostic study results
- Patents granted in USA & China
- Diagnostic test data published
- **Independent market assessment**



- Predictive test data published

Due Q2 2017

- **Validation study results – 500 patient**

Due Q2 2017

- Prototype kit manufacture complete

Due mid 2017

- **First commercial sales**

Due end 2017

Board & management



Terry Sweet FAICD, Chairman

Director of several listed companies over the past 30 years in both executive and non-executive capacities. Companies include XRF Scientific Ltd, where he was Managing Director for 4 years, Western Biotechnology Ltd, Heartlink Ltd, and Scientific Services Ltd.

Richard Lipscombe PhD (London), MA (Oxon), Founder & Managing Director

Thirty years experience in research and development globally in academic and commercial entities. Successfully managed the Company for 16 years.

Technical expertise in chemistry, immunology, & biomarker discovery.

John Dunlop PhD (UWA), BSc (UWA), Non-Executive Director

Director of several several ASX-listed companies covering mineral exploration, finance & analytical labs. Founding Director of beta-carotene producer Western Biotechnology Ltd and Founding Director of Sheen Analytical Services (which listed as Scientific Services Ltd).

Roger Moore R (Denmark), BPharm (U.Syd) Non-Executive Director

International pharmaceutical industry experience spanning 40 years, including almost 30 years as President of Novo Nordisk Japan. From 2000, he was appointed Novo Nordisk's Senior Vice President, Japan and Oceania Region. He has also served as a member of the Senior Management Board, Novo Nordisk A/S.


Chuck Morrison MBA (Boston), Bsc (Boston), Head of Business Development

37 years in life sciences, biotechnology, and diagnostic industries including DuPont and PerkinElmer.

Business model



- Three synergistic business areas
- Unifying “Promarker” platform technology
 - leverage & efficiency
- Diversified product portfolio
 - blue sky potential
 - medium term deal flow
 - existing cash flow



Why PIQ?



- **Leveraged business model**

- Established revenue ~\$1m per annum reduces burn, trending to cash flow positive
- Analytics revenue grew 34% in 2016

- **Strong IP position**

- Patents granted in major jurisdictions for ground-breaking PromarkerD diagnostic

- **Proven technology platform**

- Proof of concept established with multiple applications for bespoke diagnostic tests, e.g. Endometriosis, Mesothelioma, Gastro

- **World leading technology in an area of unmet medical need**

- Frost & Sullivan identifies “**high adoption potential**” for PromarkerD
- **Current and pending deal flow** amidst fast-growing international activity

★ 415 million, 5% uptake, \$50 test, 5% royalty, \$50 million per year

Please contact



Richard Lipscombe

Managing Director

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com

www.proteomicsinternational.com

Greg Wood


Financial Advisor, K S Capital

M: +61 416 076 377 | E: g.wood@kscapital.com.au

Susan Fitzpatrick-Napier

Media Contact, Digital Mantra Group

P: +61 2 8218 2144 | E: team@dmgpr.com



Proteomics International

LABORATORIES LTD

Supplemental: Changing lives.....

DNA shapes our lives. The Human Genome Project, to map human DNA, was the single largest undertaking in the history of biological science. Completed in 2003 it was a US\$4 billion international collaboration.

Today, cumulative benefits are estimated at US\$1 trillion, and the foundation was laid for transformational changes in medicine, from stem cell therapies to cloning.

The next generation progression of science and technology is the **proteome - the industrial scale study of the structure and function of proteins.**

Proteomics is now an integral part of the biotechnology and life sciences industries and plays an essential role in understanding disease and biological systems.

Proteomics International is acknowledged as a global leader and innovator in this field.

Why study proteomics?

These two organisms have exactly the same genome.....

